AMGN · News · 20260910N
Revenue Performance and Mix
AMGEN INC · 2026-09-10 · Importance 45 · Surprise 40 · In source text
Amgen reported Q2 2026 revenue of $10.05 billion, exceeding analyst expectations. Twenty-two products delivered at least double-digit sales growth during the quarter. Tezspire and Repatha were identified as key growth drivers, indicating continued mix contribution from newer products. The company also reported that profitability remained respectable despite cost-of-sales pressure.
Key facts
- Amgen reported quarterly earnings of $6.29 per share and revenue of $10.05 billion. source
- Q2 saw 22 products posting at least double-digit sales growth. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | unclear | realized | — | Amgen reported quarterly earnings of $6.29 per share and revenue of $10.05 billion. |
| net_income | unclear | realized | — | Amgen reported quarterly earnings of $6.29 per share and revenue of $10.05 billion. |